EBAC Accredited symposium held on August 29 2015 during ESC 2015, London, UK

Videorecordings and teaching slides


Paul M Ridker, MD
Brigham and Women’s Hospital
Harvard Medical School

Boston, USA

Kausik Ray, MD

Imperial College London
London, United Kingdom

Educational objectives were:

• Understand the unmet need for additional LDL-C-lowering therapies beyond current optimal statin-based therapy as a strategy for addressing lipid-related CV risk in patients with FH
• Understand the mechanisms and potential applications of emerging therapies to lower LDL through novel approaches that can be used in combination with statin therapy
• Describe the potential impact of PCSK9-based therapies in development in patients who require additional LDL-C reduction
• Compare and evaluate evidence from recent clinical trials of novel agents in clinical development and assess their impact on lipids and cardiovascular risk
• Understand the implications of new guidelines for lipid management

Educational programme & downloadable teaching slides

Co-Chairmen:
Wolfgang Koenig,MD - German Heart Center, Munich, Germany
Michel Farnier, MD - Point Médical, Dijon, France
 

Evolving Scientific Insights into the Novel Therapeutic Target of PCSK9

Teaching slides prepared and presented by Prof. John JP Kastelein, Amsterdam at EBAC accredited symposium ' PCSK9 inhibition in lipid management: Final steps towards implementation into clinical practice
 

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

Teaching slides prepared and presented by Prof. Paul Ridker, Boston at EBAC accredited symposium ' PCSK9 inhibition in lipid management: Final steps towards implementation into clinical practice
 

Lipid Management 2020: A glance at the future

Teaching slides prepared and presented by Prof. Kausik Ray, London at EBAC accredited symposium ' PCSK9 inhibition in lipid management: Final steps towards implementation into clinical practice

Funding

The meeting was funded by unrestricted educational grants from Amgen, Pfizer and Sanofi-Regeneron